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ABSTRACT
The purpose of this study was to evaluate the effects of the use of the subconjunctival injection of bevacizumab
(Avastin) on angiogenesis in the rat cornea. Corneas of 20 Wistar male rats were cauterized with silver nitrate crystal.
Animals were divided in four groups: control group (GC) that received subconjunctivally 0.02 ml of 0.9% saline
solution on the day of the lesion; group GO that received subconjunctivally 0.02 ml of bevacizumab just after the lesion;
group G3 that received bevacizumab on day 3 and group G5 that received bevacizumab on day 5 after lesion. Animals
were euthanized on day 7. The newly formed vessels were quantified after China Ink perfusion and photographs were
obtained and analyzed in a computerized system (Image Pro-Plus). In the control group, neovascularization covered
53.56% ± 15.11 (mean ± SD) of the corneal surface, compared with 35.57% ± 18.80 (mean ± SD) in the G0 group,
30.60%± 11.82 (mean± SD) in the G3 and 35.86%± 0.07 (mean± SD) in the G5. The results showed an inhibition of
angiogenesis when the control group was compared with all treated groups. These results suggest that subconjunctival
injection of bevacizumab is able to inhibit corneal angiogenesis independently of the day of treatment.
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INTRODUCTION
Corneal neovascularization is a sequel of several inflam-
matory disease of the anterior segment, such as infec-
tions, degenerative and traumatic disorders, reaction to
corneal transplantation and extended lens wear (Chang
et al. 2001, Hosseini and Nejabat 2007).
VEGF (Vascular Endothelial Growth Factor) has
been implicated in corneal neovascularization. The im-
plantation of nylon discs impregnated with VEGF or
bFGF (Basic Fibroblast Growth Factor) can promote
grossly prominent corneal neovascularization extending
from the limbus to the implant 7 days after the implan-
tation (Coxon et al. 2002). The application of silver ni-
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trate on the cornea induces corneal neovascularization
and increases the levels of VEGF-C e VEGFR-3 three
days after lesion (Edelman et al. 1999, Mimura et al.
2001). Other experimental models such as alkali burn
and krypton laser photocoagulation can also induce neo-
vascularization that is accompanied by increased levels
of VEGF (Gan et al. 2004, Kvanta et al. 2000).
Inhibition of VEGF and, thereby, inhibiting angio-
genesis can be an effective treatment for a variety of ocu-
lar diseases followed by neovascularization. Anti-VGEF
antibodies, such as ranibizumab (Lucentis) and pegap-
tanib (Macugen) have been designed with the aiming
to control neovascularizartion in neovascular age-related
macular degeneration (AMD) (Heier et al. 2006, Rosen-
feld et al. 2005, 2006, Gragoudas et al. 2004), prolif-
erative diabetic retinopathy (PDR) (Macugen Diabetic
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Retinophathy Study Group 2006) and corneal neovascu-
larization (Hosseini and Nejabat 2007, Manzano et al.
2006).
Bevacizumab, a humanized monoclonal anti-body
to VEGF was designed for intravenous applications and
approved for the treatment of colorectal cancer (Kab-
binavar et al. 2003, Hurwitz et al. 2004, Emmanouilides
et al. 2004). Recently bevacizumab has been used, with
promising results, as a systemic or intra-vitreal treat-
ment for exsudative AMD (Michels et al. 2005, Avery
et al. 2006a). Good results were also reported using be-
vacizumab for the treatment of diabetic retinopathy re-
ducing retina and iris neovascularization (Avery et al.
2006b, Avery 2006). One case of neovascular glaucoma
following central vein occlusion was treated with beva-
cizumab with markedly improvement of IOP and discom-
fort (Kahook et al. 2006). Bevacizumab seems to be an
effective option to inhibit corneal neovascularization. A
twice a day topic application of 4mg/ml bevacizumab for
7 days decreased corneal vascularization in 40% (Man-
zano et al. 2006). Partial regression of new vessels was
observed when Avastin was injected in the stroma of five
eyes with corneal neovascularization related to corneal
graft and limbic stem cell deficiency (Höfling-Lima et
al. 2006).
The subconjunctival injection is also a widely used
delivery method of drugs in the eye. Liu et al. (2006)
demonstrated that a single subconjuctival injection of
a VEGF trap can promote a dose-dependent regression
of newly formed vessels in a suture-induced model of
corneal neovascularization.
The aim of this paper was to study the effect of the
subconjunctival injection of bevacizumab on the exper-
imental induced corneal neovascularization in rats after
silver nitrate lesion.
MATERIALS AND METHODS
Twenty male Wistar rats, aging 8 to 10 weeks and weight-
ing 250g to 300g were used. Under general anesthe-
sia induced and maintained by isoflurane supplemented
with topical anesthesia (0.5% proparacaine hydrochlo-
ride) corneas were cauterized with silver nitrate to in-
duce neovascularization. Both corneas of each animal
were cauterized by pressing a crystal of silver nitrate,
2 mm far from the limbus, under surgical microscope.
The eyes were than carefully rinsed with approximately
10 ml of saline solution. The experiment was performed
according to the ARVO animal care regulation and ap-
proval of the local animal research ethics committee.
Following cauterization, animals were divided into
four groups: Group GC (n=10) received a subconjunc-
tival injection of 0,02 ml of 0,9% saline solution; group
GO (n=10) received a subconjunctival injection of
0,02 ml of bevacizumab (Avastin) just after the lesion;
group G3 (n=10) received a subconjunctival injection of
0,02 ml of bevacizumab (Avastin) at day 3 after lesion
and group G5 (n=10) received a subconjunctival injec-
tion of 0,02 ml of bevacizumab (Avastin) at day 5 after
lesion. Seven days after lesion, animals were euthanized
by hyper inhalation of isoflurane and corneas were per-
fused with China ink. Eyes were fixed in paraformolde-
hyde for 24 hours, dehydrated with increasing concentra-
tions of ethanol and diaphanized with benzene. Corneas
were dissected and mounted onto slides. Under mi-
croscopy photographs were taken and the newly formed
vessels were quantified and analyzed by computerized
system (Image Pro-Plus). Three standardized areas
(1350× 1020µm) were examined and an average value
was taken from each cornea. The Kruskal-Wallis test
followed by the Dunn test with P< 0.05 was used for
comparisons.
RESULTS
In the bevacizumab-treated eyes the vascular density of
new blood vessels was lower than in control eyes, inde-
pendently of the injection day. In the control group, neo-
vascularization covered 53.56% ± 15.11 (mean ± stan-
dard deviation [SD]) of the corneal surface, compared
with 35.57% ± 18.80 (mean ± SD) in the G0 group,
30.60% ± 11.82 (mean ± SD) in the G3 and 35.86%
± 0.07 (mean ± SD) in the G5 (Figs. 1 and 2). When
vascular density is compared between treated groups no
statistical differences were observed. No adverse effects
related to bevacizumab injection were observed in all
treated animals.
DISCUSSION
Many drugs as Hyperycin, Rapamycin and non-steroidal
anti-inflammatory drugs with cycloxigenase inhibitory
activity have been experimentally evaluated for corneal
neovascularization inhibition (Lavie et al. 2005, Kwon
An Acad Bras Cienc (2007) 79 (3)
SUBCONJUNCTIVAL INJECTION OF BEVACIZUMAB IN THE RAT 391
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
V
a
s
c
u
la
r 
D
e
n
s
it
y
GCL
G0L
G3L
G5L
Fig. 1 – Comparison of vascular density (mean±SD) between control group and bevacizumab treated
groups. A significant reduction of vascular density was observed in all treated groups (p< 0.05).
Fig. 2 – Images of the corneal newly formed vessels on day 7 after silver nitrate cauterization.
A) Control group [GC]; B) injection at day of lesion [G0]; C) injection at the third day after lesion
[G3]; C) injection at the fifth day after lesion [G5].
and Kim 2006, Castro et al. 2004). Among these drugs,
steroids seem to the best therapy to inhibit corneal neo-
vascularization (Riazi-Esfahani et al. 2006) and remain
the mainstay of therapy to prevent corneal graft rejection
(Randleman and Stulting 2006).
Our results suggest that bevacizumab can inhibit
corneal neovascularization in this rat model in all tested
groups. Although our data showed statistical significance
(p< 0, 05), the inhibition of corneal neovascularization
was far from complete. Some possibilities can explain
this incomplete inhibition, as insufficient dose and/or dif-
fusion and absorption of bevacizumab through the con-
junctiva with partial inhibition of VEGF activity. Besides
that, other cytokines, as FGF (Fibroblast Growth Factor)
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contributes to the angiogenic process and cannot be in-
hibited by Bevacizumb (Gaudric et al. 1992).
Bevacizumab has been successfully used systemi-
cally and intravitreally in humans with exsudative age
related macular degeneration, and diabetic retinopathy
controlling retina, choroidal and iris neovascularization
with minimal or no adverse effects (Michels et al. 2005,
Avery et al. 2006b, Avery 2006, Feiner et al. 2006). Top-
ical application of bevacizumab (4mg/ml) was effective
to control experimentally induced corneal neovascular-
ization in rats (Manzano et al. 2006). Two intrastromal
injections of 0.05 ml of Avastin with a month inter-
val were also effective to promote regression of newly
formed vessels in all studied patients (Höfling-Lima et
al. 2006).
It is interesting to observe that these findings dem-
onstrate the effect of the bevacizumab inhibition in a
short time period. There are clinical data that reveal that
bevacizumab intravitreous and intrastromal application
can be transitory and persist only for few weeks. The
observation of the effects of bevacizumab longer than
our study could be done to investigate how long the in-
hibition of neovascularization can persist.
The subconjuctival injection seems to be a good
option to inhibit corneal neovascularization. This deliv-
ery method is easy and simple to be performed, and has
minimal related complications. The possible systemic
absorption and extra ocular side effects need thought
to be adequately addressed to avoid potential compli-
cations.
We have shown that subconjuntival injection of be-
vacizumab (Avastin) is effective in controlling corneal
neovascularization in this experimental animal model.
Controlled clinical trials must be performed to demon-
strate the efficacy of bevacizumab in the treatment of
corneal neovascularization or corneal graft rejection.
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RESUMO
O objetivo deste estudo foi avaliar os efeitos da aplicação sub-
conjuntival de bevacizumab (Avastin) na angiogênese cor-
neal em ratos. Vinte ratos Wistar, machos, foram submetidos a
cauterização química com cristal de nitrato de prata. Os animais
foram divididos em 4 grupos: O grupo controle (GC), recebeu
injeção de 0,02 ml de solução fisiológica pela via subconjuntival
no momento da lesão. O grupo G0 recebeu 0,02 ml de beva-
cizumab (Avastin) imediatamente depois da lesão. O grupo
G3 recebeu 0,02 ml de bevacizumab no terceiro dia após a lesão.
O grupo G5 recebeu 0,02 ml de bevacizumab no quinto dia
após a lesão. Os animais foram eutanasiados 7 dias após a
cauterização. Os vasos neoformados foram quantificados após
preenchimento do leito vascular com Tinta da China e ima-
gens foram obtidas e analisadas em sistema computadorizado
(Image Pro-Plus). No grupo controle a neovascularização
ocupou 53,56% ± 15,11 (média ± DP) da superfície corneal
comparando a 35,57% ± 18,80 no grupo G0, 30,60% ± 11,82
(média ± DP) no G3 e 35,86% ± 0,07 (média ± DP) no G5.
Os resultados mostram uma inibição da angiogênese quando se
compara GC com os grupos tratados. Os resultados sugerem
que a injeção subconjuntival de Bevacizumab é capaz de inibir
a angiogênese corneal independentemente do dia de aplicação.
Palavras-chave: bevacizumab, córnea, neovascularização,
angiogênese.
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